Impact of pharmacogenomics on clinical practice in oncology.
Multiple drug strategies for many cancer types are now readily available and there is a clear need for tools to inform decision making on therapy selection. Although there is still a long way to go before pharmacogenomics achieves the goal of individualized selection of cancer treatment, promising progress is being made. Genetic testing for thiopurine methyltransferase (TPMT) variant alleles in patients prior to mercaptopurine administration, and for UGT1A1*28 in patients prior to administration of irinotecan therapy, along with the instigation of genotype-guided clinical trials (e.g. TYMS) are important advances in cancer pharmacogenomics. Markers for the toxicity and efficacy of many oncology drugs remain unknown; however, the examples highlighted here suggest progress is being made towards the incorporation of pharmacogenomics into clinical practice in oncology.
Marsh
Sharon
S
Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA. smarsh@im.wustl.edu
D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000235:genetics; D017850:Economics, Pharmaceutical / Q000639:trends; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D008780:Methyltransferases / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D013940:Thymidylate Synthase / Q000235:genetics; D016896:Treatment Outcome; D000099148:UGT1A1 Enzyme
D014453:Glucuronosyltransferase; D008780:Methyltransferases; D013940:Thymidylate Synthase; D000099148:UGT1A1 Enzyme; C022745:thiopurine methyltransferase